- Home
- CRVO
CRVO
CervoMed Inc.
as 11-15-2024 4:00pm EST
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 160.4M | IPO Year: | N/A |
| Target Price: | $57.60 | AVG Volume (30 days): | 81.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.85 - $26.38 | Next Earning Date: | 11-12-2024 |
| Revenue: | $10,066,550 | Revenue Growth: | 116.29% |
| Revenue Growth (this year): | 54.67% | Revenue Growth (next year): | -63.08% |
Stock Insider Trading Activity of CervoMed Inc. (CRVO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ELDER WILLIAM ROBERT | CRVO | CFO & GC | Aug 27 '24 | Buy | $18.16 | 1,000 | $18,160.00 | 1,267 |
Latest CervoMed Inc. News
CRVO Breaking Stock News: Dive into CRVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
CervoMed Announces Key Senior Leadership Appointments
GlobeNewswire
6 days ago
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
9 days ago
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
GlobeNewswire
10 days ago
CervoMed to Participate in Upcoming Investor Conferences
GlobeNewswire
13 days ago
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
GlobeNewswire
20 days ago
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
GlobeNewswire
a month ago
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
TipRanks
a month ago
CervoMed Ends $20 Million Stock Sales Agreement with BTIG
Compare CRVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVO CervoMed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.